Drug profile · INN
triflupromazine hydrochloride
VESPRIN
triflupromazine hydrochloride (VESPRIN) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — triflupromazine hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
triflupromazine hydrochloride (VESPRIN) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine D2 receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is triflupromazine hydrochloride?
triflupromazine hydrochloride (VESPRIN) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for triflupromazine hydrochloride?
VESPRIN is a marketed brand name for triflupromazine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of triflupromazine hydrochloride?
triflupromazine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.